Reviewing MindWalk (NASDAQ:HYFT) & Telesis Bio (NASDAQ:TBIO)

Telesis Bio (NASDAQ:TBIO) and MindWalk (NASDAQ:HYFT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for Telesis Bio and MindWalk, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telesis Bio	0	0	0	0	0.00
MindWalk	2	0	2	1	2.40

MindWalk has a consensus target price of $5.00, indicating a potential upside of 259.71%. Given MindWalk’s stronger consensus rating and higher probable upside, analysts clearly believe MindWalk is more favorable than Telesis Bio.

Profitability

This table compares Telesis Bio and MindWalk’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Telesis Bio	-336.59%	N/A	-61.89%
MindWalk	-89.65%	-92.61%	-54.15%

Volatility & Risk

Telesis Bio has a beta of 2.45, indicating that its share price is 145% more volatile than the S&P 500. Comparatively, MindWalk has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500.

Insider and Institutional Ownership

37.6% of Telesis Bio shares are owned by institutional investors. Comparatively, 6.7% of MindWalk shares are owned by institutional investors. 24.5% of Telesis Bio shares are owned by company insiders. Comparatively, 6.8% of MindWalk shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Telesis Bio and MindWalk”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telesis Bio	$225.09 million	0.00	-$47.72 million	($20.52)	-0.00
MindWalk	$11.24 million	5.78	-$10.11 million	($0.22)	-6.32

MindWalk has lower revenue, but higher earnings than Telesis Bio. MindWalk is trading at a lower price-to-earnings ratio than Telesis Bio, indicating that it is currently the more affordable of the two stocks.

Summary

MindWalk beats Telesis Bio on 9 of the 15 factors compared between the two stocks.

About Telesis Bio

Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications. It also provides BioXp Select kits that offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications, such as cloning, mRNA generation from plasmid, and cell free amplification; BioXp Next Generation Sequencing kits, which contains reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom Gibson short oligo ligation assembly enzymatic DNA synthesis solutions, which is designed to construct synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. The company serves its products to government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.